Cargando…

Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer

PURPOSE: Pancreatic cancer (PC) is one of the most lethal cancers worldwide, but there are currently no effective treatments. The DNA damage response (DDR) is under investigation for the development of novel anti-cancer drugs. Since DNA repair pathway alterations have been found frequently in PC, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Mei Hua, Nam, Ah-Rong, Park, Ji Eun, Bang, Ju-Hee, Bang, Yung-Jue, Oh, Do-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962488/ https://www.ncbi.nlm.nih.gov/pubmed/31291716 http://dx.doi.org/10.4143/crt.2019.183

Ejemplares similares

Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2020)

Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer
por: Park, Hyunkyung, et al.
Publicado: (2019)

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
por: Seo, Hye-Rim, et al.
Publicado: (2022)

The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy
por: Park, Hyunkyung, et al.
Publicado: (2019)

Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology
por: Ha, Hyerim, et al.
Publicado: (2019)

Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2019)

Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2019)

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
por: Ha, Hyerim, et al.
Publicado: (2016)

Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study
por: Kim, Jin Won, et al.
Publicado: (2019)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
por: Park, Woochan, et al.
Publicado: (2021)

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
por: Xing, Lijie, et al.
Publicado: (2020)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy
por: Choi, Younak, et al.
Publicado: (2016)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index
por: Choi, Younak, et al.
Publicado: (2015)

Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe
por: Din, Rahman Ud, et al.
Publicado: (2023)

WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)

Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy
por: Wang, Yu-Chu, et al.
Publicado: (2021)

More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity
por: Choi, Younak, et al.
Publicado: (2016)

Cdc25 and Wee1: analogous opposites?
por: Perry, Jennifer A, et al.
Publicado: (2007)

WEE1 inhibition sensitizes osteosarcoma to radiotherapy
por: PosthumaDeBoer, Jantine, et al.
Publicado: (2011)

Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer
por: Baek, Sun Kyung, et al.
Publicado: (2011)

WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia
por: Hu, Juncheng, et al.
Publicado: (2020)

TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
por: Kim, Jin Won, et al.
Publicado: (2020)

Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-γH2AX-MDC1
por: Zeng, Fanting, et al.
Publicado: (2022)

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
por: PARK, EUNJU, et al.
Publicado: (2011)

A Wee1 checkpoint inhibits anaphase onset
por: Lianga, Noel, et al.
Publicado: (2013)

Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair()()
por: Kausar, Tasneem, et al.
Publicado: (2015)

WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
por: Hartman, Sarah J., et al.
Publicado: (2021)

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Cell size–dependent regulation of Wee1 localization by Cdr2 cortical nodes
por: Allard, Corey A.H., et al.
Publicado: (2018)

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
por: Choi, Younak, et al.
Publicado: (2016)

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
por: Bang, Yung‐Jue, et al.
Publicado: (2019)

Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR
por: Chien, Wenwen, et al.
Publicado: (2023)

Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma
por: Lee, Kyung-Hun, et al.
Publicado: (2015)

WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma
por: Ponce, Rovingaile Kriska M., et al.
Publicado: (2022)

Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer
por: Kim, Hye-Young, et al.
Publicado: (2016)

WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
por: Lal, Shruti, et al.
Publicado: (2016)

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ubc6jmpkr96r56fbjjjsphqc5g